

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体 の編集者 名	書籍名	出版社名	出版地	ページ	出版年
Tanaka A, Gershwin ME.	Primary Biliary Cholangitis.	In: Noel R Rose, Ian R Mackay Eds.	The Autoimmune Diseases. Sixth Edition.	Elsevier	オランダ	1149-1172	2020
Tanaka A, Leung PSC, Bowlus CL, et al.	Primary Biliary Cholangitis.	In: Gershwin ME, Vierling JM, Tanaka A, Manns MP Eds.	Liver Immunology. Third Edition.	Springer	アメリカ	335-358	2020
大平 弘正	自己免疫性肝炎	小池和彦、 山本博徳、 瀬戸泰之	消化器疾患 の再診の治 療 2021-2022	南江堂	日本	260-262	2020
原田 憲一	BS4 肝内胆管癌に おける前癌・早期 癌病変、BS5 肝内 胆管癌における腫 瘍類似病変、CT1 肝門部胆管癌と肝 内胆管癌の肝門部 浸潤の区別は可能 か？	肝内胆管 癌診療ガ イドライ ン作成委 員会	肝内胆管癌 診療ガイド ライン 2021年版	金原出版	日本	27-36	2020
原田 憲一	第5章 消化器系 (7) 胆道	吉野正	カラーアト ラス 病理 組織の見方 と鑑別診断 第7版	医歯薬出 版	日本	305-313	2020
Harada K.	The Pathologist's Approach to Reviewing Liver	Editors : M. Eric Gershwin	Liver Immunology Principles	Springer	アメリカ	151-165	2020

	Histology		and Practice Third Edition				
Notohara K, Kitagawa H.	Pathology: Non-neoplastic and Neoplastic Diseases of the Gallbladder	Chung JB, Okazaki K	Diseases of the Gallbladder	Springer Nature Singapore Pte Ltd	Singapore	25-43	2020

雑誌

著者名	論文題名	雑誌名	巻(号)	ページ	発行年
Chang C, Tanaka A, Gershwin ME.	The Use of Biologics in the Treatment of Autoimmune Liver Disease.	Expt Opi Invest Drugs	29(4)	385-398	2020
Tanaka A.	Autoimmune Hepatitis: 2019 Update.	Gut and Liver	Epub ahead of print		
Tanaka A.	PBC- no longer a Western disease?	Clin Liver Dis	16(6)	227-230	2021
Tanaka A, Leung PSC, Gershwin ME.	Recurrent Autoimmune Liver Disease and its Scientific Significance.	Wiley Blackwell	-	247-261	2020
Deneau M, Valentino P, Mack C, et al.	The Sclerosing Cholangitis Outcomes in Pediatrics (SCOPE) index: a prognostic tool for children.	Hepatology	73	1074-1087	2020
Takahashi A, Ohira H, Abe K, et al.	Differences in autoimmune hepatitis based on inflammation localization.	Medl Mol Morphology	in press		
Yagi M, Matsumoto K, Komori A, et al, on behalf of Japan PBC Study Group (JPBCSG).	A validation study of the Ursodeoxycholic Acid Response Score in Japanese patients with primary biliary cholangitis.	Liver Int	40(8)	1926-1933	2020
Tanaka A, Mori	Epidemiological features of	J Hepatobiliary Pancreat	27(9)	598-603	2020

M, Kubota K, et al.	immunoglobulin G4-related sclerosing cholangitis in Japan.	Sci			
Tanaka A.	Current Understanding of Primary Biliary Cholangitis.	Clin Mol Hepatol	27(1)	1-21	2021
Takahashi A, Ohira H, Abe K, et al.	Increasing incidence of acute autoimmune hepatitis: a nationwide survey in Japan.	Sci Rep	10(1)	14250	2020
Takahashi A, Abe M, Yasunaka T, et al.	Quality of life among patients with autoimmune hepatitis in remission: A comparative study.	Medicine	99(43)	e039947	2020
田中 篤	Meeting Report-第四回 School of Hepatology in Hamamatsu	肝臓	61(2)	77-78	2020
田中 篤	自己免疫への招待：リレーエッセイ リレーエッセイの企画にあたって	肝臓	61(4)	65-66	2020
Zen Y, Kondou H, Nakazawa A, et al.	Proposal of a liver histology-based scoring system for bile salt export pump deficiency.	Hepatol Res	50(6)	754-762	2020
Oeda S, Takahashi H, Imajo K, et al.	Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan((R)) M/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: a multicenter prospective study.	J Gastroenterol	55(4)	428-440	2020
Oeda S, Takahashi H, Imajo K, et al.	Diagnostic accuracy of FibroScan-AST score to identify non-alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with non-alcoholic fatty liver disease: Comparison between M and XL probes.	Hepatol Res	50(7)	831-839	2020
Fukushima M,	Inferior Vena Cava Anomalies	Intern Med	59(22)	2897-2901	2020

Miyaaki H, Sasaki R, et al.	with Portal Vein System Continuation Presenting as Portal Hypertension with a Long-term Follow-up.				
佐々木 英之、仁 尾 正記	【最新のリスク・重症度分類に 応じた治療】胆道閉鎖症	小児外科	52(6)	603–606	2020
Uchida H, Sakamoto S, Kasahara M, et al, Japanese Liver Transplantation Society.	Longterm Outcome of Liver Transplantation for Congenital Extrahepatic Portosystemic Shunt.	Liver transplantation	27(2)	236–247	2020
Ando H, Inomata Y, Iwanaka T, et al, Japanese Biliary Atresia Society.	Clinical practice guidelines for biliary atresia in Japan: A secondary publication of the abbreviated version translated into English.	Journal of hepato-biliary-pancreatic sciences	28(1)	55–61	2021
Okubo R, Nio M, Sasaki H, the Japanese Biliary Atresia Society.	Impacts of Early Kasai Portoenterostomy on Short - Term and Long - Term Outcomes of Biliary Atresia.	Hepatology Communications	5(2)	234–243	2021
熊谷 公太郎	急性肝不全一病態解明：発症機 序から肝再生まで	日本消化器病学会雑誌	117(9)	750–755	2020
Nishikoba N, Kumagai K, Kanmura S, et al.	HGF-MET Signaling Shifts M1 Macrophages Toward an M2-Like Phenotype Through PI3K-Mediated Induction of Arginase-1 Expression.	Front Immunol	11	2135	2020
Fujiwara K, Nakayama N, Kato N, et al, Intractable Hepato-Biliary Diseases Study Group of Japan.	Infectious complications and timing for liver transplantation in autoimmune acute liver failure in Japan: a subanalysis based on nationwide survey between 2010 and 2015.	J Gastroenterol	55(9)	888–898	2020
Hisanaga T, Hidaka I,	Analysis of the safety of pretransplant corticosteroid	JGH Open	5(4)	428–433	2021

Sakaida I, et al.	therapy in patients with acute liver failure and late-onset hepatic failure in Japan.				
Genda T, Ichida T, Sakisaka S, et al.	Outcome of patients with acute liver failure awaiting liver transplantation in Japan.	Hepatol Res	50(10)	1186–1195	2020
持田 智	急性肝不全とその類縁疾患：わが国における動向	日本消化器病学会雑誌	117(9)	739–749	2020
持田 智	免疫抑制・化学療法によるB型肝炎の再活性	日本内科学会雑誌	109(9)	1790–1795	2020
Abe K, Fujita M, Hayashi M, et al.	Association of serum 25-hydroxyvitamin D levels with severe necroinflammatory activity and inflammatory cytokine production in type I autoimmune hepatitis.	PLoS One	15(12)	e0243473	2020
高橋 敦史、阿部 和道、大平 弘正	小児期にステロイド導入例の transition での対応	肝胆脾	82(3)	357–361	2021
大平 弘正	自己免疫性肝炎 (AIH)	日本医師会雑誌	149 特別号 (2)	233–234	2020
大平 弘正、阿部 和道、高橋 敦史	自己免疫性肝炎	生体の科学	71 (5)	432–433	2020
大平 弘正	自己免疫性肝疾患の最近の動向	日本内科学会雑誌	109 (9)	1878–1884	2020
大平 弘正、阿部 和道、高橋 敦史	オーバーラップ症候群を含む難治例の治療方針	消化器・肝臓内科	8 (3)	296–300	2020
阿部 和道、藤田 将史、林 学 他	自己免疫性肝炎	消化器・肝臓内科	7 (6)	538–543	2020
大平 弘正、阿部 和道、高橋 敦史	自己免疫性肝炎	日本臨牀	別冊 1	151–154	2021
Komori A.	Recent updates on the management of autoimmune hepatitis.	Clin Mol Hepatol	27	58–69	2021
原田 憲一、吉村 かおり	NAFLD/NASH の病理診断の現状	Progress in Medicine	40(5)	485–489	2020
高橋 健太、原田	肝臓のメカニズム	月刊薬事	62(2)	16–23	2020

憲一					
山村 美奈子、原田 憲一	IgG4 関連硬化性胆管炎	胆と脾	41(6)	583-587	2020
原田 憲一、吉村 かおり、高橋 健太	原発性胆汁性胆管炎の病理	日本臨牀	78(1)	78-85	2020
Amano N, Sato S, Murata A, et al.	A case of primary biliary cholangitis overlapping with type 2 autoimmune hepatitis.	Clinical Journal of Gastroenterology	13(1)	79-82	2020
Yamamura M, Sato Y, Takahashi K, et al.	The cyclin-dependent kinase pathway involving CDK1 is a potential therapeutic target for cholangiocarcinoma.	ONCOLOGY REPORTS	43	306-317	2020
Fukunishi S, Takamura M, Inoue O, et al.	Regenerative Therapy for Liver Cirrhosis Based on Intrahepatic Arterial Infusion of Autologous Subcutaneous Adipose Tissue-Derived Regenerative (Stem) Cells: Protocol for a Confirmatory Multicenter Uncontrolled Clinical Trial.	JMIR RESEARCH PROTOCOLS	9(3)	e17904 p1-7	2020
Nakagawa R, Nguyen Canh Hiep, Ouchi H, et al.	Expression of fatty-acid-binding protein 5 in intrahepatic and extrahepatic cholangiocarcinoma: the possibility of different energy metabolisms in anatomical location.	Medical Molecular Morphology	53	42-49	2020
Margaux Sala, Delphine Gonzales, Thierry Leste-Lasserre, et al.	ASS1 Overexpression: A Hallmark of Sonic Hedgehog Hepatocellular Adenomas; Recommendations for Clinical Practice.	Hepatology Communications	4(6)	809-824	2020
Nakanuma Y, Harada K, Sato Y, et al.	Gastric subtype of intraductal papillary neoplasm of the bile duct: The pathologic spectrum.	Journal of Hepato-Biliary-Pancreatic Sciences	27(7)	402-413	2020

Naitoh I, Kamisawa T, Tanaka A, et al.	Clinical characteristics of immunoglobulin IgG4-related sclerosing cholangitis: Comparison of cases with and without autoimmune pancreatitis in a large cohort.	Dig Liver Dis	Online ahead of print		
Watanabe T, Nakai Y, Mizuno S, et al.	Prognosis of Primary Sclerosing Cholangitis According to Age of Onset.	J Hepatobiliary Pancreat Sci.	Online ahead of print		
Akamatsu N, Hasegawa K, Egawa H, et al.	Donor age (≥ 45 years) and reduced immunosuppression are associated with the recurrent primary sclerosing cholangitis after liver transplantation - a multicenter retrospective study.	Transpl Int.	Epub ahead of print.		
Fujiwara K, Yasui S, Kondo T, et al.	Role of autoimmunity in patients transplanted for acute liver failure of unknown origin: A clinical and graft biopsy analysis.	Liver Transpl	27	309–310	2021
太田 正之、藤永 淳郎、多田 和裕 他	腹腔鏡下脾臓摘出術に必要な局所解剖	手術	74(5)	789–794	2020
Yamashita Y, Aishima S, Nakao Y, et al.	Clinicopathological characteristics of combined hepatocellular cholangiocarcinoma from the viewpoint of patient prognosis after hepatic resection: High rate of early recurrence and its predictors.	Hepatol Res	50(7)	863–870	2020
Takayama H, Ohta M, Iwashita Y, et al.	Altered glycosylation associated with dedifferentiation of hepatocellular carcinoma: A	BMC cancer	20(1)	192	2020

	lectin microarray-based study.				
柿坂 啓介、滝川 康裕	急性肝不全 劇症化の予知と予防(総説/特集)	日本消化器病学会雑誌	117(9)	756–762	2020
柿坂 啓介、滝川 康裕	薬物性肝障害(DILI)へのアプローチ DILI 重症化予測と治療	薬事	62 (2)	350–355	2020
柿坂 啓介、滝川 康裕	海外の診断基準 EASL-Clif Consortium と APASL ACLF Research Consortium	医学のあゆみ	272(7)	577–580	2020
Kuroda H, Abe T, Fujiwara Y, et al.	Contrast-enhanced ultrasonography-based hepatic perfusion for early prediction of prognosis in acute liver failure.	Hepatology	Online ahead of print		
Kakisaka K, Suzuki Y, Abe H, et al.	Early identification using the referral system prolonged the time to onset for hepatic encephalopathy after diagnosing severe acute liver injury.	Sci Rep	10(1)	17280	2020
Takikawa Y, Kakisaka K, Suzuki Y, et al.	Multicenter study on the consciousness-regaining effect of a newly developed artificial liver support system in acute liver failure: An on-line continuous hemodiafiltration system.	Hepatology Research	Online ahead of print		
Teraoka Y, Imamura M, Uchida T, et al.	Abatacept treatment for patients with severe acute hepatitis caused by hepatitis B virus infection–Pilot study.	J Viral Hepat.	28	400–409	2021
Akahori Y, Kato H, Fujita T, et al.	Establishment of a novel hepatitis B virus culture system using immortalized human hepatocytes.	Sci Rep.	10	21718	2020
Takeuchi Y, Tsuge M,	Signal Activation of Hepatitis B Virus-Related	J Infect Dis.	222	2061–2070	2020

Tsushima K, et al.	Hepatocarcinogenesis by Up-regulation of SUV39h1.				
Matsumoto A, Nishiguchi S, Enomoto H, et al.	Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B.	J Gastroenterol.	55	977–989	2020
Cheng X, Uchida T, Xia Y, et al.	Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection.	J Clin Invest.	130	3205–3220	2020
Gervais O, Ueno K, Kawai Y, et al.	Regional heritability mapping identifies several novel loci (STAT4, ULK4, and KCNH5) for primary biliary cholangitis in the Japanese population.	Eur J Hum Genet.	in press		
Asselta R, Paraboschi EM, Gerussi A, et al.	X chromosome contribution to the genetic architecture of primary biliary cholangitis.	Gastroenterology	in press		
Hitomi Y, Aiba Y, Kawai Y, et al.	rs1944919 on chromosome 11q23.1 and its effector genes COLCA1/COLCA2 confer susceptibility to primary biliary cholangitis.	Sci Rep	11	4557	2021
中村 稔	原発性胆汁性胆管炎	生体の科学	71 (5)	428–429	2020
人見 祐基、中村 稔	PBCの疾患感受性遺伝子と病態の関連性	肝胆膵	80 (6)	965–974	2020
Toyohara T, Nakazawa T, Zakharia K, et al.	IgG4-related Sclerosing Cholangitis Complicated with Cholangiocarcinoma and Detected by Forkhead Box P3 Immunohistochemical Staining.	Intern Med	60 (6)	859–866	2021
能登原 憲司	硬化性胆管炎の病理	胆道	34(5)	282–839	2020
Joshita S, Yamashita Y, Sugiura A, et al	Clinical utility of FibroScan as a non-invasive diagnostic test for primary biliary	J Gastroenterol Hepatol	35	1208–14	2020

a1.	cholangitis.				
Furukawa M, Moriya K, Namisaki T, et al.	Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis.	Hepatology Research	50	840-852	2020